Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CYCN
stocks logo

CYCN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Cyclerion Therapeutics Inc (CYCN.O) is -0.05, compared to its 5-year average forward P/E of -0.78. For a more detailed relative valuation and DCF analysis to assess Cyclerion Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.78
Current PE
-0.05
Overvalued PE
0.24
Undervalued PE
-1.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.17
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.33
Undervalued EV/EBITDA
-0.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.28
Current PS
0.00
Overvalued PS
22.94
Undervalued PS
-4.37
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CYCN News & Events

Events Timeline

(ET)
2025-09-23
16:08:20
Cyclerion Signs Licensing Deal with MIT and Unveils Strategic Relaunch
select
2025-05-06 (ET)
2025-05-06
16:59:34
Cyclerion Therapeutics files to sell 500K shares of common stock for holders
select
2024-12-17 (ET)
2024-12-17
07:20:51
Cyclerion Therapeutics announces update on next stage of growth
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-10Benzinga
Cycurion Secures Over $1 Million Contract to Upgrade Federal Emergency Warning System

  • Contract Announcement: Cycurion, Inc. has secured a contract with a major telecommunications company to provide network deployment services for a federal agency's modernization initiative, covering over 1,300 sites nationwide.

  • Project Details: The project, valued at over $1 million, aims to replace outdated infrastructure with a modern communication network, enhancing emergency warning capabilities over a duration of 24 to 36 months.

  • Recent Achievements: Cycurion also recently won a $1.145 million contract to modernize data systems for a large county public guardian office, migrating sensitive data to a secure Microsoft SQL Server platform.

  • Stock Performance: Following these announcements, Cycurion's stock rose by 2.08% to $2.45, although it remains near its 52-week low of $2.15.

[object Object]
Preview
7.5
09-24NASDAQ.COM
What’s Driving the Surge in Cyclerion Stock During Pre-market Trading?

  • Cyclerion's Stock Surge: Shares of Cyclerion Therapeutics Inc. rose 39.24% to $4.22 in pre-market trading following a licensing agreement with MIT, which secures intellectual property for its strategic relaunch as a neuropsychiatric company.

  • Focus on Treatment-Resistant Depression: The company plans to advance its lead program into a phase 2 trial for treatment-resistant depression (TRD) by 2026, aiming to improve therapies for this condition affecting approximately 3 million Americans.

[object Object]
Preview
9.0
09-24NASDAQ.COM
Biotech Stocks Rise After Hours Following Trial News and Strategic Developments

  • Cyclerion Therapeutics Surge: Cyclerion Therapeutics, Inc. (CYCN) saw a 48.01% increase in after-hours trading after announcing a strategic relaunch focused on neuropsychiatric therapies, including a licensing agreement with MIT for its treatment-resistant depression program, with a Phase 2 trial expected to start in 2026.

  • Clearside Biomedical Updates: Clearside Biomedical Inc. (CLSD) rose 6.82% in after-hours trading following presentations at the EURETINA Congress regarding its Phase 2b trial for wet age-related macular degeneration, with the next key milestone being the initiation of a Phase 3 trial.

  • Reviva Pharmaceuticals Conference Participation: Reviva Pharmaceuticals Holdings Inc. (RVPH) experienced an 11.50% rise in after-hours trading ahead of its participation in the Lytham Partners Fall 2025 Investor Conference, despite a decline during regular trading hours.

  • Corcept Therapeutics Data Presentation: Corcept Therapeutics Inc. (CORT) gained 4.54% in after-hours trading and announced it will present late-breaking data from its Phase 3 trial for relacorilant in ovarian cancer at the 2025 ESMO Annual Meeting, with key PDUFA dates set for late 2025 and mid-2026.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cyclerion Therapeutics Inc (CYCN) stock price today?

The current price of CYCN is 1.7 USD — it has increased 11.11 % in the last trading day.

arrow icon

What is Cyclerion Therapeutics Inc (CYCN)'s business?

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

arrow icon

What is the price predicton of CYCN Stock?

Wall Street analysts forecast CYCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYCN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cyclerion Therapeutics Inc (CYCN)'s revenue for the last quarter?

Cyclerion Therapeutics Inc revenue for the last quarter amounts to 875.00K USD, increased 351.03 % YoY.

arrow icon

What is Cyclerion Therapeutics Inc (CYCN)'s earnings per share (EPS) for the last quarter?

Cyclerion Therapeutics Inc. EPS for the last quarter amounts to -0.30 USD, increased 3.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cyclerion Therapeutics Inc (CYCN)'s fundamentals?

The market is revising No Change the revenue expectations for CYCN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -23.26%.
arrow icon

How many employees does Cyclerion Therapeutics Inc (CYCN). have?

Cyclerion Therapeutics Inc (CYCN) has 1 emplpoyees as of December 05 2025.

arrow icon

What is Cyclerion Therapeutics Inc (CYCN) market cap?

Today CYCN has the market capitalization of 6.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free